Prolonged Survival After Dichloroacetate Treatment of Non-Small-Cell Lung Carcinoma-Related Leptomeningeal Carcinomatosis

Lemmo, Walter; Tan, Gerard

doi:10.14740/jmc2456w

Cited by 2 publications

(1 citation statement)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that the DCA combination therapy blocked further tumor development. Lemmo et al [ 436 ] also described a case of prolonged survival (over a year) after DCA treatment of 500–750 mg/day of leptomeningeal carcinomatosis that originated from NSCLC. As with the studies immediately above, again, these results provide anecdotal evidence only and further clinical trials are needed before any conclusions can be drawn on the efficacy or lack of efficacy of DCA in these kinds of treatments.…”

Section: Clinical Casesmentioning

confidence: 99%

Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts

Koltai,

Fliegel

2024

Pharmaceuticals

View full text Add to dashboard Cite

Rarely has a chemical elicited as much controversy as dichloroacetate (DCA). DCA was initially considered a dangerous toxic industrial waste product, then a potential treatment for lactic acidosis. However, the main controversies started in 2008 when DCA was found to have anti-cancer effects on experimental animals. These publications showed contradictory results in vivo and in vitro such that a thorough consideration of this compound’s in cancer is merited. Despite 50 years of experimentation, DCA’s future in therapeutics is uncertain. Without adequate clinical trials and health authorities’ approval, DCA has been introduced in off-label cancer treatments in alternative medicine clinics in Canada, Germany, and other European countries. The lack of well-planned clinical trials and its use by people without medical training has discouraged consideration by the scientific community. There are few thorough clinical studies of DCA, and many publications are individual case reports. Case reports of DCA’s benefits against cancer have been increasing recently. Furthermore, it has been shown that DCA synergizes with conventional treatments and other repurposable drugs. Beyond the classic DCA target, pyruvate dehydrogenase kinase, new target molecules have also been recently discovered. These findings have renewed interest in DCA. This paper explores whether existing evidence justifies further research on DCA for cancer treatment and it explores the role DCA may play in it.

show abstract

Section: Clinical Casesmentioning

confidence: 99%